Literature DB >> 8426752

Alternative mRNA forms and open reading frames of the max gene.

I Västrik1, P J Koskinen, R Alitalo, T P Mäkelä.   

Abstract

The max gene encodes a heterodimeric partner of Myc. We have recently identified an alternative max mRNA (delta max) that contains an additional internal exon introducing an in-frame translational termination. Here we have studied the expression of human max mRNAs by Northern blotting analysis. In addition to the major 2.3-kb mRNA form, four bands were identified. Our results indicate that these bands represent differentially spliced mRNA forms, which contain altogether three open reading frames. In addition to the previously identified Max and delta Max proteins, sequence analysis of a 3.5-kb mRNA form predicted a protein that resembles delta Max in structure. Like delta Max, this protein enhanced the number of transformed foci in the ras-myc co-transformation assay. Although the 3.5-kb mRNA represents a minor form in actively proliferating cells, a shift from the major 2.3-kb mRNA to the 3.5-kb form was observed in response to high cell density or acidification of the growth medium. Our results indicate the presence of several differentially spliced mRNA forms of the max gene, and suggest a possible mechanism for the production of functionally distinct Max proteins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8426752

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  A minimal regulatory region maintains constitutive expression of the max gene.

Authors:  M A Peters; K G Sollenberger; T L Kao; E J Taparowsky
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

2.  Distinct DNA binding preferences for the c-Myc/Max and Max/Max dimers.

Authors:  D L Solomon; B Amati; H Land
Journal:  Nucleic Acids Res       Date:  1993-11-25       Impact factor: 16.971

3.  Genomic, transcriptional and mutational analysis of the mouse microphthalmia locus.

Authors:  J H Hallsson; J Favor; C Hodgkinson; T Glaser; M L Lamoreux; R Magnúsdóttir; G J Gunnarsson; H O Sweet; N G Copeland; N A Jenkins; E Steingrímsson
Journal:  Genetics       Date:  2000-05       Impact factor: 4.562

4.  EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.

Authors:  Ivan Babic; Erik S Anderson; Kazuhiro Tanaka; Deliang Guo; Kenta Masui; Bing Li; Shaojun Zhu; Yuchao Gu; Genaro R Villa; David Akhavan; David Nathanson; Beatrice Gini; Sergey Mareninov; Rui Li; Carolina Espindola Camacho; Siavash K Kurdistani; Ascia Eskin; Stanley F Nelson; William H Yong; Webster K Cavenee; Timothy F Cloughesy; Heather R Christofk; Douglas L Black; Paul S Mischel
Journal:  Cell Metab       Date:  2013-05-23       Impact factor: 27.287

5.  Expression of Mad, an antagonist of Myc oncoprotein function, in differentiating keratinocytes during tumorigenesis of the skin.

Authors:  A Lymboussaki; A Kaipainen; E Hatva; I Västrik; L Jeskanen; M Jalkanen; S Werner; F Stenbäck; R Alitalo
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

6.  Expression of the mad gene during cell differentiation in vivo and its inhibition of cell growth in vitro.

Authors:  I Västrik; A Kaipainen; T L Penttilä; A Lymboussakis; R Alitalo; M Parvinen; K Alitalo
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

7.  Differential expression of myc, max and RB1 genes in human gliomas and glioma cell lines.

Authors:  H E Hirvonen; R Salonen; M M Sandberg; E Vuorio; I Västrik; E Kotilainen; H Kalimo
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.